Skip to content
PubMed This is a summary of 17 peer-reviewed journal articles Updated
Clinical Immunology · Activated PI3K Delta Syndrome Type 2

Understanding Your APDS2 Diagnosis

At a Glance

APDS2 is a rare genetic immune disorder caused by a disease-causing change in PIK3R1. That change makes part of immune-cell signaling overactive, which can lead to recurrent infections; confirmation supports specialized care, family testing, and monitoring.

Receiving a diagnosis of APDS2 (also known as PASLI-R1) often marks the end of a long and exhausting journey. For many families, this moment follows years of unexplained infections, hospital visits, and a search for answers that didn’t seem to exist. It is common to feel a complex mix of relief that the “odyssey” is over and anxiety about what a rare genetic diagnosis means for the future [1][2].

Understanding APDS2

APDS2 stands for Activated PI3K Delta Syndrome type 2. It is an inborn error of immunity—a condition where a part of the immune system is misprogrammed from birth [3]. In the case of APDS2, the “instruction manual” for your immune cells has a specific error in a gene called PIK3R1 [3][4].

This gene is responsible for creating a protein called p85α, which acts like a brake or a regulator for a signaling pathway (the PI3K delta pathway) inside your white blood cells [5]. In APDS2, this “brake” doesn’t work correctly, causing the pathway to stay “on” or hyperactive [6]. This overactivity leads to a paradox: parts of the immune system are working too hard, while other parts are not working well enough to protect against infections [7].

Why It Took So Long

If you feel like it took an unusually long time to get here, the data confirms your experience. On average, there is a diagnostic delay of about 10.6 years between the first symptoms and a confirmed diagnosis of APDS overall [8]. Symptoms often begin in early childhood—frequently around age 2—but because the disease is so rare, it is often misidentified as more common conditions for a decade or more [8][9].

Because APDS2 is extremely rare—estimated to affect only about 1 to 2 people per million for APDS overall—most local doctors and even many general pediatricians or internists may have never seen a case before [10][11]. Reaching this diagnosis required a high level of persistence from you and your care team [2].

Validating Your Experience

The path to a diagnosis of a rare immunodeficiency is frequently marked by delayed recognition or dismissal of symptoms [2]. Research into the lives of families with these conditions shows that:

  • Emotional Burden: It is normal to experience higher levels of anxiety, sleep disruption, and stress while managing a child’s health without a clear answer [12][13].
  • Quality of Life: The constant cycle of infections and treatments can significantly impact social life, school attendance, and emotional well-being [14].
  • Caregiver Strain: The weight of coordinating care for a rare disease is substantial, and these feelings of “caregiver burden” are a recognized part of the disease experience [15].

What the Science Says Today

While the diagnosis is rare, it is also a gateway to targeted care. Unlike general immune issues, APDS2 is now understood at a molecular level.

  • Genetic Confirmation: The diagnosis is confirmed through genetic testing that identifies a pathogenic variant (a disease-causing change) in the PIK3R1 gene [3].
  • Pathway-Specific: Because scientists know exactly which pathway is overactive (PI3K delta), researchers have been able to develop treatments that specifically modulate that pathway [6].
  • Inheritance and Penetrance: APDS2 is usually an autosomal dominant condition, meaning an affected parent has a 50% chance of passing the variant to each child, though it can also occur de novo. The disease has incomplete penetrance and variable expressivity, meaning that even members of the same family with the genetic change can show widely different severities of symptoms—and some may be completely asymptomatic [16][17].

You are no longer searching for a name for what is happening. With a diagnosis in hand, you can move from wondering why these health challenges are occurring to focusing on a specific, evidence-based management plan.

Common questions in this guide

What does an APDS2 diagnosis mean?
APDS2 is a rare genetic disorder of the immune system. It is caused by a disease-causing change in PIK3R1 that makes the PI3K delta signaling pathway too active, which can leave a person prone to recurrent infections.
How is APDS2 confirmed?
APDS2 is confirmed when genetic testing identifies a disease-causing variant in the PIK3R1 gene. Knowing the specific variant can help the care team discuss the condition, family testing, and possible disease course, although symptoms can vary widely.
Can APDS2 run in families?
Yes. APDS2 is usually autosomal dominant, so a parent with the PIK3R1 variant has a 50% chance of passing it to each child. The condition can also arise de novo, meaning the genetic change occurs for the first time in a person, and not everyone with the variant has symptoms.
Why can APDS2 take years to diagnose?
APDS2 often begins in early childhood, but it is rare and may resemble more common illnesses. Families may therefore see multiple doctors before the underlying cause is recognized; studies of APDS overall report an average diagnostic delay of about 10.6 years.
Will everyone with the same PIK3R1 change have the same symptoms?
No. Incomplete penetrance and variable expressivity mean that people in the same family with the PIK3R1 change can have very different symptoms and severity. Some people with the genetic change may have no symptoms.
What should happen after an APDS2 diagnosis?
After diagnosis, ask for care from a clinical immunologist familiar with immune signaling disorders. The care plan may include managing infections, considering pathway-specific treatment, monitoring for long-term complications, and discussing genetic testing for relatives with a genetic counselor.

Get notified when new evidence is published on immunodeficiency 132b.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (17)
  1. 1

    "It's a Godsend": Parental experiences of genomic testing for paediatric inborn errors of immunity.

    Clark A, DeBortoli E, Blancoe M, et al.

    European journal of human genetics : EJHG 2025; (33(10)):1342-1349 doi:10.1038/s41431-025-01917-7.

    PMID: 40730688
  2. 2

    Time to diagnosis for a rare disease: managing medical uncertainty. A qualitative study.

    Phillips C, Parkinson A, Namsrai T, et al.

    Orphanet journal of rare diseases 2024; (19(1)):297 doi:10.1186/s13023-024-03319-2.

    PMID: 39143641
  3. 3

    Hyperactivation of the PI3K pathway in inborn errors of immunity: current understanding and therapeutic perspectives.

    IJspeert H, Dalm VASH, van Zelm MC, Edwards ESJ

    Immunotherapy advances 2024; (4(1)):ltae009 doi:10.1093/immadv/ltae009.

    PMID: 39679264
  4. 4

    Infections in activated PI3K delta syndrome (APDS).

    Brodsky NN, Lucas CL

    Current opinion in immunology 2021; (72()):146-157 doi:10.1016/j.coi.2021.04.010.

    PMID: 34052541
  5. 5

    Conformational disruption of PI3Kδ regulation by immunodeficiency mutations in PIK3CD and PIK3R1.

    Dornan GL, Siempelkamp BD, Jenkins ML, et al.

    Proceedings of the National Academy of Sciences of the United States of America 2017; (114(8)):1982-1987 doi:10.1073/pnas.1617244114.

    PMID: 28167755
  6. 6

    Enhanced AKT Phosphorylation of Circulating B Cells in Patients With Activated PI3Kδ Syndrome.

    Asano T, Okada S, Tsumura M, et al.

    Frontiers in immunology 2018; (9()):568 doi:10.3389/fimmu.2018.00568.

    PMID: 29675019
  7. 7

    Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase δ syndrome 2: A cohort study.

    Elkaim E, Neven B, Bruneau J, et al.

    The Journal of allergy and clinical immunology 2016; (138(1)):210-218.e9 doi:10.1016/j.jaci.2016.03.022.

    PMID: 27221134
  8. 8

    Genetic Etiologies and Outcomes in Malignancy and Mortality in Activated Phosphoinositide 3-Kinase Delta Syndrome: A Systematic Review.

    Büsch K, Memmott HL, McLaughlin HM, et al.

    Advances in therapy 2025; (42(2)):752-771 doi:10.1007/s12325-024-03066-7.

    PMID: 39636570
  9. 9

    A single center experience on PI3K/AKT/MTOR signaling defects: Towards pathogenicity assessment for four novel defects.

    Bildik HN, Esenboga S, Halaclı SO, et al.

    Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology 2024; (35(9)):e14245 doi:10.1111/pai.14245.

    PMID: 39312287
  10. 10

    Diagnostic odyssey of patients with the rare immunodeficiency activated PI3 kinase delta syndrome (APDS): case study from expert and patient surveys.

    Wolf HM, Candotti F, Spelsberg R, et al.

    Frontiers in immunology 2026; (17()):1763482 doi:10.3389/fimmu.2026.1763482.

    PMID: 41859081
  11. 11

    Case report on activated PI3K-delta syndrome.

    Crisanto-López IE, Pérez-Arzola AA, Hernández-Castañeda Y, et al.

    Boletin medico del Hospital Infantil de Mexico 2024; (81(4)):245-249 doi:10.24875/BMHIM.23000124.

    PMID: 39236673
  12. 12

    Psychological State of Parents of Children with Primary Immunodeficiencies During the COVID-19 Pandemic.

    Akdağ B, Önder A, Gizli Çoban Ö, et al.

    Pediatric allergy, immunology, and pulmonology 2022; (35(1)):12-18 doi:10.1089/ped.2021.0081.

    PMID: 35180363
  13. 13

    Immunodeficiency: Burden of Illness.

    Hsueh JC, Van Hersh AT, Zhao W

    Allergy and asthma proceedings 2024; (45(5)):294-298 doi:10.2500/aap.2024.45.240060.

    PMID: 39294910
  14. 14

    Health-related quality of life in patients with inborn errors of immunity: A systematic review and meta-analysis.

    Xiao N, Huang X, Yang D, et al.

    Preventive medicine 2024; (186()):108079 doi:10.1016/j.ypmed.2024.108079.

    PMID: 39053518
  15. 15

    When cure is not enough: Parental anxiety, depression, and caregiver burden after HSCT for inborn errors of immunity.

    Aydemir S, Durcan G, Nurhan E, et al.

    Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology 2026; (37(11)).

    PMID: 42969273
  16. 16

    Activated phosphoinositide 3-kinase δ syndrome: Update from the ESID Registry and comparison with other autoimmune-lymphoproliferative inborn errors of immunity.

    Maccari ME, Wolkewitz M, Schwab C, et al.

    The Journal of allergy and clinical immunology 2023; (152(4)):984-996.e10 doi:10.1016/j.jaci.2023.06.015.

    PMID: 37390899
  17. 17

    Clinical and immunological assessment of APDS2 with features of the SHORT syndrome related to a novel mutation in PIK3R1 with reduced penetrance.

    Szczawińska-Popłonyk A, Bernat-Sitarz K, Schwartzmann E, et al.

    Allergologia et immunopathologia 2022; (50(4)):1-9 doi:10.15586/aei.v50i4.510.

    PMID: 35789397

This page is for informational purposes only and does not constitute medical advice. A clinical immunologist and genetic counselor can interpret your PIK3R1 result and discuss individualized care and family testing.